Morphic Holding Stock Price, News & Analysis

Morphic Therapeutic reported positive topline results from the EMERALD-1 Phase 2a study of MORF-057, an oral inhibitor targeting the α4β7 integrin for ulcerative colitis treatment. The trial enrolled 35 participants and demonstrated a statistically significant reduction in the Robarts Histopathology Index (RHI) score by 6.4 points (p=0.002) at week 12. Additionally, 25.7% of patients achieved clinical remission according to the Modified Mayo Clinic Score (mMCS). MORF-057 was generally well tolerated, showing no serious adverse events. The company is progressing with the ongoing EMERALD-2 Phase 2b study.

Morphic Therapeutic (Nasdaq: MORF) announced pivotal results from its EMERALD-1 Phase 2a trial on MORF-057 for ulcerative colitis, meeting its primary endpoint with a significant reduction in the Robarts Histopathology Index score by 6.4 points (p=0.002) at week 12. The trial reported a 25.7% remission rate via the Modified Mayo Clinic Score. The drug was well tolerated, showing no safety signals. The ongoing EMERALD-2 Phase 2b trial is fully enrolled and on track for results in early 2025. Financially, Morphic ended Q1 2023 with $421 million in cash, extending its operational runway into 2026. However, it reported a net loss of $36.1 million, increasing from $31.5 million year-over-year, and generated revenue of only $0.5 million compared to $2.4 million the previous year.

Morphic Therapeutic will host a conference call on April 25, 2023, to discuss topline results from the EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The study includes a main cohort of 35 patients treated with 100 mg BID. The primary endpoint evaluated the change in the Robarts Histopathology Index (RHI) after 12 weeks, assessing histological disease activity. The trial aims to demonstrate the efficacy, safety, and tolerability of MORF-057, a selective oral inhibitor of the α4β7 integrin, which has shown promise in targeting inflammatory bowel disease. A live webcast will be available on the company’s website, and an archived replay will follow.

Morphic Therapeutic (Nasdaq: MORF) announced its participation in the TD Cowen 43rd Annual Health Care Conference, focusing on innovative treatments for gastroenterological diseases. The management team will engage in a GI/Microbiome Panel Discussion at 9:10 AM ET and a Fireside Chat at 11:10 AM ET on March 6, 2023. A live webcast will be accessible on the Investor section of Morphic's website, with an archived replay available afterward. Morphic is dedicated to developing oral integrin therapies for serious chronic diseases, supported by its proprietary MInT technology platform and collaborations with Janssen.

Morphic Therapeutic (Nasdaq: MORF) announced the completion of enrollment for its EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis, with topline data expected in 2Q23. The company also launched the EMERALD-2 phase 2b global trial for the same drug. At the end of 2022, Morphic reported $348 million in cash and equivalents, bolstered by a $100 million private placement in February 2023 to extend its cash runway into the second half of 2026. The company showed a significant increase in revenue to $70.8 million for 2022, compared to $19.8 million in 2021, although net losses decreased from $95.5 million in 2021 to $59 million in 2022.

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company focused on oral integrin therapies, will participate in the virtual SVB Leerink Global Healthcare conference on February 16, 2023. The event will feature a fireside chat scheduled for 8:40 AM ET. A live webcast will be available on the Investor section of Morphic's website, with an archived replay accessible following the conference. Morphic is developing treatments for serious chronic diseases such as autoimmune, cardiovascular, and metabolic diseases, leveraging its innovative MInT technology platform in collaboration with Janssen.